On September 6, 2019, Zhang, Xingxian; He, Kailun; Wang, Wenbing; Wang, Xiaoju; Zheng, Xiaoliang published a patent.HPLC of Formula: 882518-89-0 The title of the patent was Compound targeting EGFR protein degradation useful in treatment of cancer and its preparation. And the patent contained the following:
The invention relates to compounds of formula I and II targeting EGFR protein degradation useful in treatment of cancer and its preparation Compounds I and II, wherein R is C1-6 alkyl; m is an integer of 1-7; n is an integer of 1-6; their pharmaceutically acceptable salts, are claimed. The inventive compound shows excellent EGFR-degrading action and high antitumor activity, and can be applied in cancer prevention and/or treatment. The experimental process involved the reaction of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate(cas: 882518-89-0).HPLC of Formula: 882518-89-0
The Article related to pyrimidine derivative preparation treatment cancer egfr degrading, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.HPLC of Formula: 882518-89-0
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics